ProShare Advisors
KRTX

ProShare Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

ProShare Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,406
Closed -$1.08M – 2030
2023
Q4 		$1.08M Buy
3,406
+943
+38% +$183K ﹤0.01% 744
2023
Q3 		$416K Buy
2,463
+41
+2% +$7.71K ﹤0.01% 1009
2023
Q2 		$525K Sell
2,422
-3,791
-61% -$812K ﹤0.01% 926
2023
Q1 		$1.13M Sell
6,213
-519
-8% -$99.3K ﹤0.01% 708
2022
Q4 		$1.32M Buy
6,732
+582
+9% +$125K ﹤0.01% 682
2022
Q3 		$1.38M Buy
6,150
+871
+16% +$176K 0.01% 676
2022
Q2 		$667K Sell
5,279
-1,969
-27% -$226K ﹤0.01% 851
2022
Q1 		$918K Sell
7,248
-1,769
-20% -$199K ﹤0.01% 957
2021
Q4 		$1.18M Sell
9,017
-142
-2% -$18.4K ﹤0.01% 946
2021
Q3 		$1.12M Sell
9,159
-1,894
-17% -$219K ﹤0.01% 864
2021
Q2 		$1.26M Buy
11,053
+3,093
+39% +$362K ﹤0.01% 905
2021
Q1 		$957K Buy
7,960
+324
+4% +$36.7K ﹤0.01% 1016
2020
Q4 		$776K Buy
7,636
+1,413
+23% +$131K ﹤0.01% 1002
2020
Q3 		$481K Sell
6,223
-59
-0.9% -$5.03K ﹤0.01% 956
2020
Q2 		$700K Buy
6,282
+2,083
+50% +$181K ﹤0.01% 813
2020
Q1 		$302K Sell
4,199
-2,048
-33% -$175K ﹤0.01% 870
2019
Q4 		$471K Buy
+6,247
New +$274K ﹤0.01% 1095

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

ProShare Advisors's KRTX Position: Q1 2024 in Review

ProShare Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 3,406 shares — an estimated $1.08M sold.

ProShare Advisors first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $1.38M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • ProShare Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • ProShare Advisors sold 3,406 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.08M.
  • ProShare Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • ProShare Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $1.38M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on ProShare Advisors's 13F filing for Q1 2024, filed 8 May 2024.